27 results
Thumbnail

D3.323 - SBK007: A Novel Oral H1 Antihistamine with Rapid Onset (30min): Preclinical Pharmacodynamics in Acute Urticaria

Thumbnail

D3.324 - Hereditary Angioedema Attack Frequency and Severity According to Individuals Taking Berotralstat for Long-Term Prophylaxis

Thumbnail

D3.325 - Immediate-type allergic reactions associated with thiuram mix sensitization in an adolescent with atopic dermatitis: a case report

Thumbnail

D3.328 - Paediatric Anaphylaxis: The Importance Of Recognition

Thumbnail

D3.329 - Real-world shelf-life of adrenaline auto-injectors (AAIs) at pharmacy dispensing: Insights from six countries

Thumbnail

D3.331 - Real-World Challenges in Pediatric Anaphylaxis: The Role of Epinephrine

Thumbnail

D3.332 - Patient Preferences for Nasal Adrenaline Spray versus Adrenaline Auto-Injectors in Anaphylaxis: A Multi-Country Discrete Choice Experiment

Thumbnail

D3.333 - Clinical Characteristics of Anaphylaxis in Infants and Toddlers

Thumbnail

D3.334 - Severe Early-Onset Atopy With Recurrent Anaphylaxis and Infections as Indicators of CADINS Disease

Thumbnail

D3.335 - Anaphylaxis After Eating Sushi - Emergent allergies with new food habits?

Thumbnail

D3.418 - A Phase 1b Study of Lesigercept, a Long-acting High-affinity IgETrap-Fc Fusion Protein: Safety, Tolerability, PK, and PD in Atopic Healthy and Allergic Subjects

Thumbnail

D3.419 - Efficacy, safety, and remission outcomes of omalizumab in elderly patients with severe allergic asthma: a subgroup analysis by age of onset

Thumbnail

D3.420 - Real-world epidemiologic characteristics of patients treated with dupilumab for type 2 inflammatory indications: a single-center retrospective cohort study

Thumbnail

D3.421 - Real-world Effectiveness and Safety of Lanadelumab Treatment in Patients With Hereditary Angioedema: The 12-Month Interim Analysis of a Polish, Prospective, Multicenter, Observational Study (CHOPIN)

Thumbnail

D3.422 - Dupilumab in children with multimorbid atopic phenotype: therapy efficacy, safety and biomarker changes

Thumbnail

D3.423 - Lanadelumab treatment is effective and safe in patients with Factor XII associated cold-induced autoinflammatory syndrome: results from an open-label proof-of-concept study

Thumbnail

D3.424 - Retrospective Analysis of Self-Administration of Biologic Treatments for Severe Asthma and Chronic Urticaria

Thumbnail

D3.426 - Predicting response to omalizumab in patients with chronic spontaneous urticaria: The first results of the global multicenter UCARE SCOPUS project

Thumbnail

D3.427 - Challenging the paradigm: Use of omalizumab in refractory angioedema in a 2-year-old child

Thumbnail

D3.428 - Substratification of Biologic Treatment Using Dupilumab in Eosinophilic COPD